<DOC>
	<DOCNO>NCT00275457</DOCNO>
	<brief_summary>To evaluate safety efficacy pramipexole treatment patient suffer moderate severe RLS 6 week double blind condition follow 46 week open label double blind extension .</brief_summary>
	<brief_title>Efficacy Safety Pramipexole ( PPX ) Moderate Severe Idiopathic Restless Legs Syndrome ( RLS ) Patients</brief_title>
	<detailed_description>To evaluate safety efficacy pramipexole treatment patient suffer moderate severe RLS 6 week double blind condition follow 46 week open label double blind extension Study Hypotheses : Null hypothesis : No difference pramipexole placebo RLSRS total score baseline difference CGI-I responder rate end 6 week double-blind treatment . Comparison ( ) : Pramipexole v . Placebo</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female outpatient age 1880 2 . Diagnosis idiopathic RLS accord Clinical RLS criteria International RLS Study Group . All four criterion must present : Irresistible urge move usually associate sensory complaint low limb Motor restlessness Worsening symptom rest least partial temporary relief activity Increased severity even night 3 . RLS rating scale severity score &gt; 15 4 . RLS symptoms present least 2 3 day per week within last 3 month 5 . Written inform consent consistent ICH/GCP local legislation give prior study procedure 6 . Ability willingness comply study treatment regimen attend study assessment Exclusion criterion : 1 . Women childbearing potential , use adequate protection barrier protection , intrauterine device , hormonal ( oral subcutaneous ) contraception postmenopausal woman le 6 month last menses , surgically sterilise , oophorectomised hysterectomised less 3 month operation use adequate protection woman neither use adequate protection postmenopausal partner sterilise least 6 month post operation use condom , woman negative serum pregnancy test screen 2 . Males use adequate form contraception ( condom , sterilisation least 6 month post operation ) 3 . Patients breastfeed 4 . Concomitant previous pharmacologically therapy RLS follow : Any intake levodopa within 5 day prior baseline visit ( V2 ) Any intake dopamine agonist within 14 day prior baseline visit ( V2 ) History intake pramipexole 5 . Current ( less 14 day treatment trial medication concomitant ) treatment medication dietary supplement , could significantly influence RLS symptom withdrawal symptom cause stop drug 6 . Confirmed diagnose diabetes mellitus require insulin therapy 7 . Clinically significant renal disease creatinine high upper limit normal ( ULN ) screen 8 . Clinically significant hepatic disease sGPT &gt; 2 time upper limit normal range screen 9 . Clinical laboratory sign microcytic anaemia investigator discretion 10 . Any following lab result screen : Hb erythrocyte count lower limit normal ( LLN ) Basal TSH , T3 T4 clinically significantly ( investigator 's discretion ) normal range screening ( cause substitution therapy accord investigator 's opinion ) 11 . Other clinically significant metabolicendocrine , haematological , gastrointestinal disease pulmonary disease . Poorly control cardiovascular disease 12 . History clinical sign peripheral neuropathy ( PNP ) origin physical , neurological examination , myelopathy multiple sclerosis neurological disease , potential secondarily cause RLS symptom 13 . Presence sleep disorder , , REM sleep behaviour disorder , narcolepsy sleep apnoea syndrome 14 . History Schizophrenia psychotic disorder , history mental disorder due general medical condition present axis I psychiatric disorder accord DSM IV require medical therapy history alcohol abuse drug addiction within last 2 year screen 15 . Participation drug study within two month prior start study 16 . History clinical sign form epilepsy seizure apart fever related seizure early childhood 17 . History clinical sign malign neoplasm 18 . Patients shiftworkschedule , otherwise unable follow regular sleepwake cycle enable use study medication time indicate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>